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Physician-patient communication about genomic tumor testing: 
perceptions of oncology providers 
• Genomic tumor testing (GTT) is a new technology and a 
cornerstone of the “precision medicine” movement in cancer 
care.
• GTT uses next-generation genome sequencing technology to 
identify somatic variants in tumor cells.
• By identifying somatic variants that predict responses to cancer 
therapies, GTT can help tailor therapy to individual patients, 
making them more effective.
• However, due to the fact that GTT also detects many variants of 
uncertain significance, its clinical value is currently unproven.
• When using GTT, physicians counsel patients about both its 
benefits and its limitations, but the ideal goals and content of 
these physician-patient discussions have not been clearly 
defined. 
Background
Objective
Explore providers’ perceptions of the key goals and elements of 
physician-patient discussions about GTT.
Methods
• Qualitative analysis of open-ended responses to questionnaire 
administered to health professionals participating in the 
Jackson Laboratory’s Maine Cancer Genomics Initiative (MCGI), 
a 5-year state-wide research project aimed at disseminating 
and implementing GTT in community oncology practices 
throughout the state of Maine.
• In April 2018, 120 physicians and clinical staff attended an 
annual 2-day MCGI conference, convened by The Jackson 
Laboratory to educate and update providers on the progress of 
the initiative.
• Surveys consisted of both multiple-choice and open-ended 
questions, designed to assess perceptions of the key goals and 
elements of physician-patient discussions of GTT.
Open-ended question (Key elements)
“Given what you know about GTT, how would you introduce it to a 
patient? Identify three (3) essential things the patient needs to 
know.”
• Qualitative thematic analysis of open-ended items, software-
assisted coding with MAXQDA™
Conclusions
• Cancer care providers identify three main goals and elements of 
provider-patient discussions to introduce GTT to patients:
1. Educate patients about the nature of the test including 
scientific background, aspects of the testing process, and the 
meaning of somatic vs. germline testing. 
2. Convey the goals and purpose of GTT, largely focused on the 
identifying actionable variants for treatment decision-
making. 
3. Manage patient expectations regarding the value of GTT.
• Providers describe the goals and purpose of GTT using mixed 
language that conveys both the value of GTT and uncertainty 
about its value. 
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Future Research Directions
• Replicate and assess the generalizability of the findings in a 
larger, more diverse sample.
• Assess patients’ perceptions of the goals and ideal content of 
physician-patient discussions of GTT.
• Develop and test patient education and decision support 
interventions to facilitate informed and shared decision making 
about GTT.
Illustrative Quotations from Open-Ended Responses
Nature of GTT
Scientific explanation “The reason that cancers that look the same don’t respond the same is because of different 
genetic changes inside the cancer cell”
Testing process “Testing done on tumor tissue removed during surgical procedure”
Type of test “Whether the test will focus on tumor or both tumor and germline”
Goals and Purpose Certain Value Uncertain Value
Treatment Planning “This is a way to utilize precision medicine and 
offer a more personalized treatment based on 
cancer genomics and identifying specific genes 
and mutations associated with patient’s 
individual cancer”
“We hope the result will help guide future 
treatment options, however we do not always 
find mutations that we can take action on or 
change treatment”
Diagnostic Use “Different than genetic testing, will classify 
tumor”
“Real chance that test may not yield any results 
or may yield results that are vague or non-
actionable”
Prognostic Use “That the test is not perfect and does not 
determine outcome”
“Impact of information re: treatment/family/ 
prognosis and limitations of what can be 
learned”
Manage Patient Expectations
Assess and attend to patient 
literacy
“Basic knowledge/explanation of germline vs. somatic mutation (assess baseline health 
literacy)”
Discuss likelihood of benefit “Benefits and limitations of the testing and how likely it is to provide information that would 
lead to a therapeutic change, i.e. manage expectations”
Oncology Providers 17
Registered Nurses 14
Genetic Counselors 5
Pathologists 5
Other (e.g. practice administrators, other physicians) 35
Total Participants 76
o Scientific explanation
o Testing process
o Type of test – somatic vs. 
germline
Explain the nature of testing
Goals and purpose of testing
o Treatment planning
o Diagnostic use
o Prognostic use
Provider-patient discussion about genomic tumor testing
Provider language used in discussing 
value of testing
Certain Value
Uncertain Value
• Assess and attend to patient literacy
• Discuss likelihood of benefit
Managing patient expectations of 
the value of testing
Negative Sentiment
• “Does not”
Positive Sentiment
• “Will”
Positive Sentiment
• “Can”
Negative Sentiment
• “Might not”
Balanced Sentiment
• “May or may not”
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